ABSI — Absci Corporation

Earnings Call Summary for Absci Corporation (Q1 2026)

1. Key Financial Results and Metrics:

• Revenue: $200,000 for Q1 2026, primarily from partnered programs.
• R&D Expenses: Increased to $19.3 million from $16.4 million year-over-year, reflecting advancement in internal programs, particularly ABS-201.
• SG&A Expenses: Decreased to $9.1 million from $9.5 million, mainly due to reduced personnel costs.
• Cash Position: $125.7 million as of March 31, 2026, down from $144.3 million at year-end 2025. This is projected to fund operations into 2028.

2. Strategic Updates and Business Highlights:

• ABS-201 Progress: The Phase 1/2a trial is on track, with preliminary safety and pharmacokinetics (PK) data expected next month, interim proof-of-concept (POC) data in the second half of 2026, and full POC data in early 2027.
• New Pipeline Addition: Announcement of ABS-202, an anti-prolactin receptor antibody targeting an undisclosed inflammatory and immune indication.
• Focus on Prolactin Biology: The company is expanding its research into prolactin biology, which is seen as underexplored and has potential applications beyond current indications.
• AI Integration: Implementation of agentic AI workflows is expected to enhance efficiency across research and administrative functions.

3. Forward Guidance and Outlook:

• Upcoming Catalysts: Key upcoming milestones include preliminary safety and PK data for ABS-201, interim 13-week hair regrowth data, and initiation of a Phase 2 trial for endometriosis.
• Market Potential: ABS-201 is projected to tap into significant market opportunities, with estimates suggesting a total available market exceeding $25 billion for androgenic alopecia (AGA) and potential peak sales of over $4 billion for endometriosis.
• Strategic Priorities: Continued focus on developing differentiated therapeutic assets and exploring partnerships for early-stage programs.

4. Bad News, Challenges, or Points of Concern:

• Deprioritization of Oncology Programs: Absci has decided to deprioritize certain oncology programs, which may limit diversification in their pipeline.
• Market Competition: The evolving competitive landscape in hair regrowth therapies raises questions about the necessity of demonstrating superior efficacy compared to existing treatments like oral minoxidil.
• Clinical Trial Risks: The high placebo response historically observed in pain studies for endometriosis poses a challenge for the upcoming trials, necessitating careful execution and monitoring.

5. Notable Q&A Insights:

• ABS-202 Mechanism: Management indicated that ABS-202 will have a differentiated profile and is exploring indications beyond AGA and endometriosis.
• Efficacy Expectations: For ABS-201, comparable efficacy to oral minoxidil with infrequent dosing is seen as a potential market differentiator. The 13-week readout is expected to be directional, with definitive results anticipated at 26 weeks.
• Patient Preferences: High interest in ABS-201 was noted, particularly among patients already dissatisfied with current treatments, suggesting a strong market entry potential.
• Regulatory Engagement: The company is actively engaging with the FDA regarding its development strategy, particularly for ABS-201 and the endometriosis trial.

Overall, Absci Corporation is positioned for a data-rich year with significant upcoming milestones, although it faces challenges related to market competition and clinical trial execution.